ReCAP

 
 
  • Chronic Lymphocytic Leukemia Highlights From ASH 2022   Dr Jan Burger reports on key data in chronic lymphocytic leukemia from ASH 2022, focusing on treatment-free remission, triple combination therapy, and BTK inhibitors pirtobrutinib and zanubrutinib.
  • Breakthroughs in Mantle Cell Lymphoma From ASH 2022   The beginning of the end for upfront stem cell transplants and chemotherapy, plus novel relapsed/refractory therapies, are among Dr Peter Martin's highlights in mantle cell lymphoma from ASH 2022.
  • Key Data in Non-Hodgkin Lymphoma From ASH 2022   The best consolidation therapy in CNS lymphoma, bispecific antibodies, and rituximab vs watch and wait are among top picks in non-Hodgkin lymphoma from ASH 2022, reported by Dr Michael Bishop.
  • Highlights in Multiple Myeloma From ASH 2022   Dr Joseph Mikhael selects new data on bispecific antibodies, racial and ethnic differences in outcomes, and encouraging results from novel therapies as his multiple myeloma highlights from ASH 2022.
  • Advances in CAR-T Cell Therapy From ASH 2022   Novel CD7 and CD22 targets and improved outcomes with idecabtagene vicleucel and lisocabtagene maraleucel are among the advances in CAR T-cell therapy from ASH 2022, as selected by Dr Michael Bishop.
  • Top Studies in HER2+ Breast Cancer From SABCS 2022   Top studies in HER2+ breast cancer from SABCS 2022 include initial findings of the DESTINY-Breast03 and -Breast02 trials, and de-escalation strategies for patients with stage I HER2+ disease.
  • Top Studies in Metastatic Breast Cancer From SABCS 2022   Top studies in metastatic breast cancer from SABCS 2022 focus on practice-changing therapies for HR+/HER2- breast cancer, a follow-up of the monarchE trial, and results of the POSITIVE trial.
  • Highlights in Obesity From ACG 2022   Key updates in obesity management from ACG 2022 include risk factors for acute pancreatitis in patients taking GLP-1 receptor agonists and management of NAFLD, as reported by Dr Carolyn Newberry.
  • Highlights in Breast Cancer From SITC 2022   The tumor microenvironment and immunotherapy response, a novel metastatic target, and an anti-cancer vaccine are among the breast cancer highlights from SITC 2022 reported by Dr Jennifer Guerriero.
  • Advances in Non-Small Cell Lung Cancer From SITC 2022   The role of gene mutations in outcomes and treatment resistance, a novel LAG-3 inhibitor, and the case for neoadjuvant therapy are among the NSCLC highlights from SITC 2022 reported by Dr Jack West.
  • Psoriatic Arthritis Highlights From ACR 2022   Promising data from ACR 2022 on psoriatic arthritis, including long-range results on deucravacitinib and bimekizumab and a study on the novel molecule, izokibep, are presented by Dr Philip Mease.
  • Highlights in Metastatic Kidney Cancer Treatment From IKCS 2022   Highlights in kidney cancer from IKCS 2022 include updates on the CLEAR and CheckMate 214 trials, results from the TIVO-3 trial, and early data on a bacterial supplement to enhance immune therapy.
  • Diabetes and Heart Disease Highlights From AHA 2022   Key abstracts related to diabetes and heart disease from AHA 2022 include a meta-analysis of cardiovascular results from the EMPA-KIDNEY trial and new findings from the Diuretic Comparison Project.
  • Highlights in Diabetes and Metabolism From ASN 2022   From ASN 2022, Dr Carol Wysham highlights data on glucose-lowering drugs in patients with T2D, including empagliflozin and semaglutide, and a link between cognitive disorders and albuminuria.
  • Advances in Multiple Sclerosis From ECTRIMS 2022   A novel BTK inhibitor, prevention of disease progression by dimethyl fumarate, and a revamping of standard care are among multiple sclerosis advances from ECTRIMS 2022 noted by Prof Gavin Giovannoni.
  • Highlights in Esophageal Research From ACG 2022   Highlights in esophageal diseases from ACG 2022 include data on use of dupilumab in eosinophilic esophagitis, achalasia as risk for esophageal cancer, and vonoprazan in nonerosive reflux disease.
  • Key Abstracts in COPD From CHEST 2022   Key abstracts in COPD from CHEST 2022, as reported by Dr Nicola Hanania, focus on spirometry use, exacerbation risks, home rehabilitation, and triple therapy after a second moderate exacerbation.
  • Highlights in Asthma Therapy From CHEST 2022   From CHEST 2022, Dr Navitha Ramesh reports key data on biologic therapies for asthma patients, including results from the CLEAR study and trials on omalizumab, benralizumab, and tezepelumab.
  • Highlights in Corneal Disorders From AAO 2022   Key data in corneal disorders from AAO include a nontransplant therapy for Fuchs dystrophy, data on corneal adverse events from a myeloma drug, and positive data on lotilaner for Demodex blepharitis.
  • Myasthenia Gravis Highlights From AANEM   Data on therapeutic advances, including Fc receptor antagonists and complement inhibitors, top the myasthenia gravis highlights from AANEM 2022. Also reported is the effect of COVID-19 on MG patients.